The pharmaceutical industry is in the midst of a digital revolution; technology investments and data-driven decision-making are constantly on the …
Mineralys Therapeutics’s oral hypertension therapy, lorundrostat, has met the primary endpoint in two pivotal studies, boosting the company’s stock price. The …
PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy and safety of Versamune …
Novo Nordisk’s investors are unimpressed by Phase III trial data of the weekly injectable weight loss therapy, CagriSema, which fell …
A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads to …
Eli Lilly’s Ebglyss (lebrikizumab-lbkz) has achieved complete skin clearance after three years in 50% of patients with moderate-to-severe atopic dermatitis …
Amgen and Kyowa Kirin have reported that the 24-week Phase III IGNITE trial assessing two dose strengths of the T-cell …
AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab) with standard-of-care fluorouracil, leucovorin, oxaliplatin, …
Johnson & Johnson (J&J) is dropping its Phase III major depressive disorder (MDD) programme for aticaprant due to ‘insufficient efficacy …
ImmunoGenesis has initiated the first subject dosing in a multicentre Phase I/II trial of IMGS-101 (evofosfamide), the hypoxia reversal agent, …
As patient voices get amplified across platforms, finding effective ways to further enhance participation and let patient-driven inputs drive clinical …
Closing the gap in health interventions between men and women could add $1tn to the global gross domestic product (GDP) …
Merck KGaA’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but development …
Hutchmed has concluded enrolment of its multi-centre Phase II trial of fanregratinib (HMPL-453), a treatment for intrahepatic cholangiocarcinoma (IHCC) individuals …
Everest Medicines has dosed the first subject with EVM16, the company’s personalised messenger ribonucleic acid (mRNA) cancer vaccine, in the …
